Open | - |
Close | - |
Volume / Avg. | 0 / 73.223K |
Day Range | - - - |
52 Wk Range | 1.660 - 8.565 |
Market Cap | $267.463M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 62 |
Short Interest | 3.79% |
Days to Cover | 5.08 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Prelude Therapeutics (NASDAQ: PRLD) through any online brokerage.
Other companies in Prelude Therapeutics’s space includes: bluebird bio (NASDAQ:BLUE), FibroGen (NASDAQ:FGEN), Gritstone Bio (NASDAQ:GRTS), Century Therapeutics (NASDAQ:IPSC) and Black Diamond Therapeutic (NASDAQ:BDTX).
The latest price target for Prelude Therapeutics (NASDAQ: PRLD) was reported by JMP Securities on Wednesday, March 13, 2024. The analyst firm set a price target for 7.00 expecting PRLD to rise to within 12 months (a possible 43.74% upside). 8 analyst firms have reported ratings in the last year.
The stock price for Prelude Therapeutics (NASDAQ: PRLD) is $4.87 last updated March 27, 2024 at 4:56 PM EDT.
There are no upcoming dividends for Prelude Therapeutics.
Prelude Therapeutics’s Q1 earnings are confirmed for Monday, May 6, 2024.
There is no upcoming split for Prelude Therapeutics.
Prelude Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.